Author

Jonathan D Steckbeck

Peptilogics - Cited by 1,501 - Peptide Antibiotics - Membrane Protein Biochemistry - Technology Commercialization

Biography

Jonathan D Steckbeck works at  Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America. His area of research interests includes Infectious diseases, Virology, Medicine. He /she has authored of many research articles/books in relevent areas.
Title
Cited by
Year
Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens
B Deslouches, JD Steckbeck, JK Craigo, Y Doi, TA Mietzner, ...Antimicrobial agents and chemotherapy 57 (6), 2511-2521, 2013201
171
2013
Antimicrobial peptides: new drugs for bad bugs?
JD Steckbeck, B Deslouches, RC MontelaroExpert opinion on biological therapy 14 (1), 11-14, 2014201
151
2014
Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens
B Deslouches, JD Steckbeck, JK Craigo, Y Doi, JL Burns, RC MontelaroAntimicrobial agents and chemotherapy 59 (2), 1329-1333, 2015201
114
2015
C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic
JD Steckbeck, AS Kuhlmann, RC MontelaroJournal of General Virology 94 (Pt 1), 1-19, 2013201
66
2013
Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in …
JD Steckbeck, JK Craigo, CO Barnes, RC MontelaroJournal of Biological Chemistry 286 (31), 27156-27166, 2011201
48
2011
Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes
JD Steckbeck, C Sun, TJ Sturgeon, RC MontelaroPloS one 5 (12), e15261, 2010201
46
2010
Comparative functional properties of engineered cationic antimicrobial peptides consisting exclusively of tryptophan and either lysine or arginine
B Deslouches, ML Hasek, JK Craigo, JD Steckbeck, RC MontelaroJournal of medical microbiology 65 (6), 554, 2016201
37
2016
Membrane structure correlates to function of LLP2 on the cytoplasmic tail of HIV-1 gp41 protein
AL Boscia, K Akabori, Z Benamram, JA Michel, MS Jablin, JD Steckbeck, ...Biophysical journal 105 (3), 657-666, 2013201
23
2013
Structural and Functional Comparisons of Retroviral Envelope Protein C-Terminal Domains: Still Much to Learn
JD Steckbeck, AS Kuhlmann, RC MontelaroViruses 6 (1), 284-300, 2014201
21
2014
Novel engineered cationic antimicrobial peptides display broad-spectrum activity against Francisella tularensis, Yersinia pestis and Burkholderia pseudomallei
S Abdelbaqi, B Deslouches, J Steckbeck, R Montelaro, DS ReedJournal of medical microbiology 65 (2), 188-194, 2016201
21
2016
Detailed topology mapping reveals substantial exposure of the “cytoplasmic” C-terminal tail (CTT) sequences in HIV-1 Env proteins at the cell surface
JD Steckbeck, C Sun, TJ Sturgeon, RC MontelaroPloS one 8 (5), e65220, 2013201
17
2013
Unique functional properties of conserved arginine residues in the lentivirus lytic peptide domains of the C-terminal tail of HIV-1 gp41
AS Kuhlmann, JD Steckbeck, TJ Sturgeon, JK Craigo, RC MontelaroJournal of Biological Chemistry 289 (11), 7630-7640, 2014201
13
2014
A phase 1 study of the safety, tolerability, and pharmacokinetics of single ascending doses of a first-in-human engineered cationic peptide, PLG0206, intravenously administered …
D Huang, D Dobbins, P Ghahramani, I Friedland, J SteckbeckAntimicrobial Agents and Chemotherapy 66 (1), e01441-21, 2022202
10
2022
Artificial intelligence engine architecture for generating candidate drugs
F Lee, JD Steckbeck, H HolsteUS Patent 11,09,590, 2021202
4
2021
The engineered antibiotic peptide plg0206 eliminates biofilms and is a potential treatment for periprosthetic joint infections
D Huang, N Pachuda, JM Sauer, D Dobbins, J SteckbeckAntibiotics 11 (1), 1, 2021202
4
2021
Engineered peptide PLG0206 overcomes limitations of a challenging antimicrobial drug class
DB Huang, KM Brothers, JB Mandell, M Taguchi, PG Alexander, ...Plos one 17 (9), e0274815, 2022202
3
2022
Prospective Activity of PLG0206, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components Ex Vivo: The …
Prospective Activity of PLG006, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components Ex Vivo: The …D Huang, DM Parker, JB Mandell, KM Brothers, CG Gish, JA Koch, ...Microbiology Spectrum 9 (3), e01879-1, 010
2
2021
Artificial intelligence engine architecture for generating candidate drugs
F Lee, JD Steckbeck, H HolsteUS Patent App. 7/339,520, 20220
1
2021
Artificial intelligence engine for generating candidate drugs using experimental validation and peptide drug optimization
F Lee, JD Steckbeck, H HolsteUS Patent App. 7/403,94, 2022202
1
2022
Generating anti-infective design spaces for selecting drug candidates
F Lee, JD Steckbeck, H HolsteUS Patent App. 7/39,839, 2022202
1
2022

Referred From: https://scholar.google.com/citations?user=0b4S7moAAAAJ&hl=en

Cited by
Citations 1501
h-index 18
i10-index 22
Recommended Journals
Open Access Journals